Plain-English translation of NCT04594187 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether patients with melanoma that has spread to sentinel lymph nodes should receive radiation therapy in addition to immunotherapy. Half of the participants will receive both immunotherapy and focused radiation therapy to the lymph node area, while the other half will receive immunotherapy alone. The study wants to find out if adding the radiation therapy helps prevent the cancer from coming back in the lymph nodes.
Melanoma that has reached the lymph nodes carries a high risk of returning in that area even after surgery. Doctors want to know if this treatment approach can reduce that risk and improve outcomes for patients.
You likely qualify if…
You likely don't qualify if…
If you are accepted, you will be randomly assigned to one of two groups: one receiving both immunotherapy and radiation therapy (5 brief radiation sessions over 2–2.5 weeks), and the other receiving immunotherapy alone. You will have follow-up appointments every 3 months for the first 2 years, then every 6 months for the next 3 years to monitor how you are doing. The study will compare how long it takes for cancer to return in the lymph nodes between the two groups.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States